
Vivos Therapeutics (VVOS) Stock Forecast & Price Target
Vivos Therapeutics (VVOS) Analyst Ratings
Bulls say
Vivos Therapeutics Inc. reported a significant 76% year-over-year increase in revenue for Q3 FY25, primarily driven by the contributions from its Sleep Center Network (SCN), which suggests the effectiveness of their new model in accelerating market adoption and revenue growth without substantial additional investment. Service revenue more than doubled in this period to $4.6 million, highlighting robust demand particularly for sleep testing and treatment-center services, while projections indicate continued revenue growth as the company expands its Special Operations (SO) teams. Additionally, the company's clinical results demonstrate high efficacy, with significant improvements in patients with moderate to severe obstructive sleep apnea, further enhancing its market position as awareness of sleep disorders rises, especially in the fast-growing Asia Pacific region.
Bears say
Vivos Therapeutics Inc. is experiencing a negative financial outlook primarily due to a 9% year-over-year decline in total revenue for the first half of 2025, attributed to a transition from their legacy business model to a new direct sleep center management channel. Despite a quarterly revenue increase of 27% from Q1 to Q2 FY25, sales remain below projections, and gross margins have decreased to 55% due to discounting and alterations in the product and service mix. The company faces multiple risks, including projected sales growth challenges, difficulties in capital acquisition for operational expansion, and a longstanding history of operating losses, which contribute to an uncertain path toward achieving sustained profitability.
This aggregate rating is based on analysts' research of Vivos Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Vivos Therapeutics (VVOS) Analyst Forecast & Price Prediction
Start investing in Vivos Therapeutics (VVOS)
Order type
Buy in
Order amount
Est. shares
0 shares